Lv11
50 积分 2021-06-04 加入
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
4小时前
已完结
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
10天前
已完结
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer
12天前
已关闭
Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinoma
21天前
已完结
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
26天前
已完结
Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer
27天前
已关闭
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
29天前
已完结
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
1个月前
已完结
Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer
1个月前
已完结
Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC)
1个月前
已关闭
皖公网安备34019202002308
